SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

Monoclonal antibody targeting of IL-3 receptor   with CSL362 effectively depletes CML progenitor and stem cells

(2013) E. Nievergall et al.   BLOOD

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia

(2010) Hyun Pyo Kim et al.   LEUKEMIA RESEARCH

Characterization of variant diphtheria toxin–interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials

(2009) Yunpeng Su et al.   BIOLOGICALS

Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia

(2009) M. Djokic et al.   HAEMATOLOGICA

High rates of durable response are achieved with imatinib after treatment with interferon   plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial

(2009) F. Guilhot et al.   HAEMATOLOGICA

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

(2009) Bin-Bing S. Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

(2008) Arthur Frankel et al.   LEUKEMIA & LYMPHOMA